GlassScriptPhysician profile
John R Ellington
NPI 1750353918
$2,232.97
in general payments reported to CMS, 2019-2025
29 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $661 · 2020: $117 · 2021: $240 · 2022: $475 · 2023: $371 · 2024: $258 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $739.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $324.81 | 2019-2025 | Injectafer |
| Ascend Therapeutics US, LLC | $202.94 | 2019-2021 | |
| Abbvie INC. | $187.09 | 2019-2024 | |
| Astellas Pharma US INC | $155.57 | 2022-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $155.50 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.67 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $118.25 | 2021-2024 | |
| Myriad Women'S Health, INC. | $113.15 | 2023 | Myrisk |
| Myovant Sciences INC. | $109.27 | 2021-2022 | |
| Therapeuticsmd, INC. | $97.56 | 2019-2022 | |
| Millicent US INC | $93.79 | 2023-2025 | Femlyv, Intrarosa, Femring |
| Scynexis, INC. | $59.32 | 2022 | |
| Coopersurgical, INC. | $56.95 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $51.24 | 2022 | |
| Mylan Pharmaceuticals INC. | $50.11 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $45.47 | 2019 | |
| Roche Diagnostics Corporation | $37.70 | 2019 | |
| Avion Pharmaceuticals | $36.19 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $28.76 | 2019 | |
| Hologic Sales and Service, LLC | $25.26 | 2023 | Aptima, Thinprep 2000 Processor |
| Sumitomo Pharma America, INC. | $23.38 | 2024 | Gemtesa |
| Novo Nordisk INC | $23.28 | 2022 | |
| Exeltis, USA INC. | $22.01 | 2021 | |
| Mycovia Pharmaceuticals, INC. | $19.85 | 2023 | Vivjoa |
| Amag Pharmaceuticals, INC. | $16.41 | 2019 | |
| Agile Therapeutics, INC. | $14.93 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.02 | 2023 | Austedo Xr |
| Boston Scientific Corporation | $13.58 | 2019 | |
| Vertical Pharmaceuticals, LLC | $11.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ellington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.